|Videos|December 6, 2021
ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer
Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Advertisement
Data from the following clinical trials are discussed:
- 1382P - Phase 1b/2 open-label, randomized evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-gastric cancer (
MORPHEUS ) 1372O - CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system- LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
KRYSTAL-1
Advertisement
Related to this article
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Precision Advances Have Transformed Lung Cancer Care, But Key Barriers Persist
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5